T cells and macrophages are the primary targets for human immunodeficiency virus (HIV) infection and replication (13, 19, 20) , while megakaryocytes (43) and dendritic cells (23, 28) have been shown to harbor virus in HIV type 1 (HIV-1)-infected patients. Not only are mature T cells implicated in HIV infection, but recent studies have demonstrated the presence of HIV in developing thymocytes in clinical samples and in animal models of T-cell differentiation (1, 38, 39) . Infection occurring during differentiation in the thymic microenvironment could have a severe pathological impact on an infected individual's ability to maintain or regenerate a functional peripheral T-cell compartment (for a recent review, see reference 15). In order to be effective, interventive therapies, such as gene therapy, might have to reduce viral load not only in the circulation and in peripheral lymphoid compartments but also in primary hematolymphoid organs, such as bone marrow and the thymus. To establish protection in the various myeloid and lymphoid lineages within each of these compartments, it has been suggested that therapeutic anti-HIV-1 genes be transduced into hematopoietic stem-progenitor cells (HSPC) (7).
T cells and macrophages are the primary targets for human immunodeficiency virus (HIV) infection and replication (13, 19, 20) , while megakaryocytes (43) and dendritic cells (23, 28) have been shown to harbor virus in HIV type 1 (HIV-1)-infected patients. Not only are mature T cells implicated in HIV infection, but recent studies have demonstrated the presence of HIV in developing thymocytes in clinical samples and in animal models of T-cell differentiation (1, 38, 39) . Infection occurring during differentiation in the thymic microenvironment could have a severe pathological impact on an infected individual's ability to maintain or regenerate a functional peripheral T-cell compartment (for a recent review, see reference 15) . In order to be effective, interventive therapies, such as gene therapy, might have to reduce viral load not only in the circulation and in peripheral lymphoid compartments but also in primary hematolymphoid organs, such as bone marrow and the thymus. To establish protection in the various myeloid and lymphoid lineages within each of these compartments, it has been suggested that therapeutic anti-HIV-1 genes be transduced into hematopoietic stem-progenitor cells (HSPC) (7) .
Murine retroviruses, such as Moloney murine leukemia virus (MMLV), have been used extensively as vectors to stably introduce genes into HSPC. Stable integration of foreign therapeutic genes into HSPC chromatin should result in maintenance of that gene in all progeny cells, whether of myeloid or lymphoid lineage, and equally in precursors as well as in terminally differentiated cells (12) . Moreover, as the hematopoietic stem cell (HSC) component of HSPC is purported to be self-renewing, introduction of therapeutic genes into HSPC might be the best approach to confer long-term efficacy, thereby maximizing the gene's therapeutic value. Recent reports from clinical trials involving adenine deaminase-deficient patients support this hypothesis. Those studies indicated that introduction of transduced autologous HSPC resulted in the presence of gene-marked cells for a greater period of time than did introduction of transduced primary T cells in the same patient (6) .
The HIV-1 regulatory protein rev is required for the transport of unspliced and singly spliced HIV-1 mRNAs from the nucleus into the cytoplasm and is essential for the expression of HIV structural proteins (24) . The trans-dominant mutant form of HIV-1 rev, RevM10, has been shown to be effective in inhibiting HIV replication in both cell lines and in primary T cells following MMLV-mediated transfer of the RevM10-encoding gene into target cells (3, 25) . In addition, expression of the trans-dominant protein has not resulted in any adverse effects on normal cell functions (17) .
Prior to the implementation of HSPC-based human gene therapy trials, additional questions should be addressed in preclinical studies. Can HSPC be transduced with MMLV vectors expressing RevM10, and following transduction, can they still give rise to cells of the T-cell and macrophage lineages in vivo? Moreover, can RevM10-transduced HSPCs carry the transgene and maintain its expression throughout the process of in vivo lymphoid and myeloid differentiation? Finally, will the level of RevM10 expression at the end of this process be sufficient to inhibit HIV replication? To address these questions in the T-cell lineage, we have used the SCID-hu thymus/ liver (Thy/Liv) mouse model as an in vivo tool for studying the differentiation of transduced HSPC into T cells.
As reported earlier, SCID-hu Thy/Liv mice contain a vascularized conjoint organ derived from the fusion of implanted human fetal thymus and liver fragments (26) . While the liver component of the graft contributes HSC elements, the thymus provides the microenvironment for T-cell differentiation (31) . These and additional characteristics of the SCID-hu mouse have been previously reviewed in detail (27) . Intrathymic injection of allogeneic (HLA-mismatched) CD34 ϩ cells, but not CD34 Ϫ , bone marrow, umbilical cord blood (CB), or mobilized peripheral blood (MPB) cells, into irradiated SCID-hu Thy/Liv grafts has been used to demonstrate and characterize the in vivo differentiation potential of HSPC into the T-cell lineage (11, 30) . Champseix et al., using a retrovirus-based vector, recently showed that CD34 ϩ CB HSPC carrying a transgeneencoded cell surface marker could differentiate in vivo in the SCID-hu thymus model and ultimately express the marker after differentiating into thymocytes (9) . We have previously reported thymic reconstitution experiments in which CB HSPC were transduced with an MMLV vector carrying both the RevM10 gene and the gene coding for neomycin resistance and were subsequently transplanted into Thy/Liv grafts of SCID-hu mice. In these studies, donor-derived T cells demonstrated marking levels of approximately 0.01 to 0.1% as measured by DNA PCR and were also shown to express the transgene (33) . These marking efficiencies are similar to those reported in recent clinical studies (12) . We used a modified MMLV vector, LMiLy, which encodes the transmembrane and cytoplasmic portions of the cell surface marker Lyt2 (the murine homolog of human CD8␣) linked via an internal ribosomal entry sequence (IRES) to the RevM10-encoding sequence (21) . Such constructs have been shown to be useful for detection and/or enrichment of transduced cells by flow cytometry and other means of positive selection (10, 29) . Here, we show that transduced CB and MPB HSPC give rise to phenotypically normal thymocytes in the SCID-hu Thy/Liv model and that MMLVdriven transgene expression is readily detected in these HSPC progeny. Furthermore, we demonstrate that the therapeutic gene for RevM10 is expressed at levels sufficient to inhibit HIV replication, providing preclinical evidence for the feasibility of HSPC gene therapy in the treatment of AIDS.
MATERIALS AND METHODS
Retrovirus vector construction and supernatant preparation. The compositions of the recombinant retrovirus vectors are shown in Fig. 1A . Each of the recombinant retroviruses utilizes the MMLV long terminal repeat enhancerpromoter for transgene expression. LMiLy was derived from the LMTNL vector (14) by exchanging the tkNeo drug selection marker with the IRES-Lyt2 gene. The IRES-Lyt2 sequence consists of the IRES of the human encephalomyocarditis virus (21) linked to the murine gene coding for the cell surface CD8␣ (Lyt-2␣Ј) antigen (kindly provided by G. P. Nolan, Stanford University). The Lyt2 gene used in these vectors had its cytoplasmic tail deleted as described previously in detail (40) . L⌬MiLy contains a mutated RevM10 gene (⌬M10) lacking the methionine initiation codon (35) . In addition, a 50-bp linker, 5Ј-GA TCTGCTACGTGCATCGCTACCTGACTAGCTGACAGGCCATTCTGGCC T-3Ј, has been inserted into the BglII site of the ⌬M10 gene (Fig. 1A) and encodes an additional series of stop codons in all three reading frames. Amphotropic retrovirus vector supernatants were prepared as described previously (16) , using the ProPak-A packaging cell line (36) . All producer cells tested negative for the presence of replication-competent retroviruses by S ϩ L Ϫ assay on PG4 cells (18) . Antibodies and growth factors. The following mouse monoclonal antibodies were used as previously described (11): anti-CD34 sulfa-rhodamine (SR) and FIG. 1. RevM10 and control vectors encoding the selectable surface marker Lyt2. (A) A schematic representation of the MMLV-based therapeutic and control retrovirus vectors illustrates the order of the encoding sequences for either RevM10 or ⌬RevM10 and the membrane-expressed murine (mu) CD8␣Ј (Lyt2). Transcription is driven directly from the 5Ј long terminal repeat, yielding a single transcript. Translation of Lyt2 from the transcript is directed by the IRES sequence. This feature permits detection of RevM10 expression through flow cytometric analysis of transgene-encoded surface Lyt2 expression. The ⌬RevM10-encoding sequence has been modified such that the translational start codon has been mutated from a start ATG to a stop TAG codon sequence. A 50-nucleotide (n.t.) insertion was engineered into the 3Ј region of the ⌬RevM10 sequence. The inserted sequence codes for additional translational stop codons in all three reading frames. (B) Freshly isolated CD4 ϩ CD8 Ϫ human fetal thymocytes were activated and transduced with LMiLy or L⌬MiLy retrovirus supernatants. Transduced cells were enriched to Ͼ90% for surface Lyt2 expression by several rounds of flow cytometric sorting. Cells were subsequently restained for detection of transgene-encoded surface Lyt2, fixed, made permeable, and costained for detection of nuclear Rev (RevM10).
fluorescein isothiocyanate (FITC)-conjugated anti-CD2, -CD4 (Leu3a), -CD14, -CD15, -CD16, -CD19, and glycophorin A. The previously listed FITC-conjugated antibodies comprised the lineage marker (LIN) panel used in these studies. The MA2.1 (FITC) antibody was prepared at SyStemix from hybridomas obtained from the American Type Culture Collection (Rockville, Md.). Phycoerythrin (PE)-conjugated anti-CD4 (Leu3A) and anti-CD34 were also purchased from Becton Dickinson. OKT4-FITC was purchased from Ortho Diagnostics. PE-conjugated anti-Lyt2 was purchased from Pharmingen. Biotinylated anti-CD8 was purchased from Becton Dickinson. TRI-COLOR anti-CD3 and anti-CD8 were purchased from Caltag.
The following growth factors were used: recombinant human interleukin-2 (IL-2), obtained from Cellular Products; and recombinant human IL-3, purchased from R&D Systems or provided by Sandoz; and recombinant human IL-6, stem cell growth factor (SCF), and leukemia inhibitory factor (LIF), obtained from Sandoz.
Isolation of CD34 ؉ cells and retrovirus transduction. Human CB samples were collected and processed essentially as previously described (11, 33) . Prior to cryopreservation, an aliquot of each tissue was subjected to HLA phenotyping (MA2.1). After being thawed, CD34 ϩ cells were enriched by immunomagnetic bead selection. Briefly, cells were resuspended at 5 ϫ 10 7 /ml in RPMI containing 2% heat-inactivated fetal calf serum (FCS) plus 10 mM HEPES (selection buffer) and 1 mg of human serum gamma globulin (Gamimmune; Miles, Inc.) per ml. Cells were incubated 5 min at 4°C; then anti-CD34 antibody (QBEND-10; Immunotech) was added at 4 g/ml, after which the mixture was incubated for 15 to 20 min at 4°C. Samples were washed and then resuspended at 2 ϫ 10 7 cells/ml. CD34 ϩ cells were positively selected by using goat anti-mouse immunoglobulin G1 magnetic beads (Dynal) in accordance with the manufacturer's recommendations. Following selection, bound cells were incubated with 50 l of glycoprotease (O-sialoglycoprotein endopeptidase; Cedarlane) at 37°C for 30 min, which released the cells from the immunomagnetic beads. The beads were removed magnetically, and the cells were assessed for CD34 content by flow cytometry following staining for lineage markers with anti-CD34 PE and a panel of FITC-conjugated antibodies.
MPB HSPC samples were obtained from patients with multiple myeloma who were being treated with cyclophosphamide (6 g/m 2 ) and granulocyte-macrophage colony-stimulating factor (0.25 mg/m 2 ) or from healthy granulocyte colonystimulating factor mobilized donors at the University of Arkansas Medical Center and from Baxter Biotech Immunotherapy Division, Irvine, Calif., respectively, with informed consent from the donors. Leukophoresis samples were enriched for CD34 ϩ cells by use of an immunomagnetic bead selection device (Baxter Healthcare Corporation). Enrichment for CD34 ϩ cells for both CB and MPB was generally Ͼ90%. Prior to freezing of CD34-selected MPB tissues, as with CB samples, an aliquot of each tissue was subjected to HLA phenotyping (MA2.1).
As shown in Fig. 2 , following enrichment, CD34 ϩ HSPC were thawed and briefly cultured in the presence of IL-3, IL-6, and either SCF or LIF. They were then subjected to two rounds of transduction by spinoculation, as described in detail previously (33) , with either LMiLy or L⌬MiLy supernatants. CD34 ϩ cells were cultured at 5 ϫ 10 5 to 10 ϫ 10 5 cells/ml in Whitlock-Witte medium (50% Iscove's modified Dulbecco medium [50% RPMI 1640, 10% FCS, 4 ϫ 10 Ϫ5 M 2-mercaptoethanol, 5 mM sodium pyruvate, 10 mM HEPES, 100 U of penicillin per ml, 100 mg of streptomycin per ml, and 4 mM glutamine) supplemented with IL-3, IL-6, and either SCF or LIF. Retrovirus gene transfer was performed by incubating 5 ϫ 10 5 to 10 ϫ 10 5 cells with vector supernatants at a ratio of 1:1 in Whitlock-Witte medium plus cytokines (IL-3, IL-6, and either SCF or LIF) and 4 g of protamine sulfate per ml for 3 to 4 h while centrifuging at 2,000 ϫ g and 21 to 32°C. At 48 h after the second transduction, cells were stained for surface CD34 (SR), Lyt2 (PE), and lineage markers (FITC) and sorted for CD34-positive, LIN-negative as well as Lyt2 ϩ or Lyt2 Ϫ phenotypes on a Vantage or FACStar cell sorter (Becton Dickinson Immunocytometry Systems). Propidium iodide was added (1 g/ml) immediately prior to sorting to facilitate the exclusion of dead cells through the setting of propidium iodide-negative sort gates. Mock transductions were carried out identically to retrovirus transduction, except no viral supernatants were added during the centrifugation steps.
Analysis of thymocytes from SCID-hu mice. The SCID-hu mice were constructed by surgical transplantation of human fetal thymus and liver fragments into C.B-17 scid/scid mice as previously described (31) and in accordance with the guidelines set forth by the SyStemix Animal Care and Use Committee. All thymus and liver tissues had been identified as positive or negative for expression of the HLA MA2.1 marker. Three to five months posttransplantation of thymus and liver fragments, SCID-hu mice, whose Thy/Liv grafts were HLA mismatched (MA2.1) with respect to donor HSPC, were given 400 rads of total body irradiation, after which they were subjected to HSPC reconstitution, as described previously in detail (11) . LMiLy-or L⌬MiLy-transduced HSPC (3 ϫ 10 4 to 20 ϫ 10 4 ) which had been sorted for surface Lyt2 expression, as well as the CD34-positive and LIN-negative phenotypes, were injected directly into Thy/Liv grafts in SCID-hu mice. Control mice were injected with either mock-transduced unsorted HSPC or phosphate-buffered saline alone. Between 7 and 9 weeks after reconstitution, thymocytes were recovered from the grafts and analyzed for the level of donor reconstitution (MA2.1 FITC), the phenotypic distribution of CD4 and CD8 antigen expression (CD4, FITC or PE; CD8, TRI-COLOR), and the expression of the LMiLy-or L⌬MiLy-encoded Lyt2 (Lyt2 PE) by flow cytometry (FACScan; Becton Dickinson). Thymocytes were also examined for transgene marking by DNA PCR, as previously described (33) , with rev primers.
HIV-1 infection of transduced HSPC-derived RevM10-expressing thymocytes.
Thymocytes from HSPC-reconstituted SCID-hu Thy/Liv mice were stimulated in vitro in medium (RPMI 1640, 10% FCS, 50 g of streptomycin per ml, 50 U of penicillin G per ml, 1ϫ MEM vitamin solution [GIBCO BRL], 1ϫ insulintransferrin-sodium selenite medium supplement [Sigma], 20 to 40 U of human recombinant IL-2 per ml, 2 g of phytohemagglutinin [PHA; Sigma] per ml) in the presence of allogeneic irradiated feeder cells (10 6 peripheral blood mononuclear cells/ml and 10 5 JY cells/ml). Cells were subsequently maintained in medium without feeder cells or PHA. Every 9 to 12 days, cells were restimulated with feeder cells and PHA as described previously in detail (41) . Three to five days after stimulation, cells were stained for donor HLA (MA2.1 FITC) and for transgene-encoded Lyt2 (Lyt2 PE). Cells were sorted by donor phenotype and additionally sorted for the Lyt2 ϩ phenotype. Sorted cells were expanded and resorted until Ͼ90% were of the donor HLA composition and Lyt2-positive cells were Ͼ90% pure. Finally, cells were restimulated, and three to four days later they were sorted for CD4-positive (OKT4) and Lyt2-positive phenotypes. Sort purities were between 90 and 99%. A portion (5 ϫ 10 4 ) of each group of sorted cells was placed in quadruplicate wells in 96-well round-bottom tissue culture plates in 100 l of medium. Either 200 to 400 50% tissue culture infective doses (TCID 50 s) of the primary isolate of HIV-1, EW, or 1,000 TCID 50 s of the molecular isolate of HIV-1, JR-CSF, were added to each of the wells. Virus stocks were prepared as previously described (5). The medium was changed every day, and supernatants were collected daily from day 3 to day 12. Supernatants were assayed for p24 by using a p24 enzyme-linked immunoassay (ELISA) kit (Coulter).
Flow cytometric dual detection of transgene-encoded RevM10 and Lyt2. Freshly isolated human fetal thymocytes were stained with biotinylated anti-CD8 mouse monoclonal antibodies (Becton Dickinson) and then immunodepleted with streptavidin-coated magnetic beads (Dynal) in accordance with the manufacturer's instructions. The resulting cells were Ͼ90% CD4 ϩ CD8
Ϫ . Cells were stimulated with PHA and irradiated allogeneic feeders as described above. Cells were transduced with either LMiLy or L⌬MiLy supernatants by the protocol described above for HSPC transduction. Following transduction, Lyt2-expressing cells were purified to Ͼ90% purity by cell sorting. After expansion, cells were first stained for surface Lyt2 and then fixed, made permeable, and stained intracellularly for rev (RevM10) as previously described (37) . Cells were subsequently analyzed on a FACScan (Becton Dickinson Immunocytometry Systems).
1A. The LMiLy vector has been described previously and encodes both RevM10 and a truncated version of the murine homolog of human CD8␣, Lyt2, which is lacking its cytoplasmic signalling domain (40) . The control vector (L⌬MiLy) differs from the antiviral vector in that expression of RevM10 has been abrogated by insertional mutations. The bicistronic messages generated by each vector permit the rapid determination of transduction and expression in target cells by flow cytometric detection of the surface Lyt2 antigen. In order to demonstrate that surface detection of Lyt2 can be used as an indicator of RevM10 expression, freshly isolated CD4 ϩ thymocytes were transduced with either LMiLy or L⌬MiLy retrovirus supernatants. These CD4 ϩ cells were purified for Lyt2 expression to Ͼ90% by several rounds of cell sorting and costained for both transgene-encoded proteins, nuclear RevM10 and surface Lyt2. As shown in Fig. 1B, both 
Transduction and selection of HSPC. CB and MPB HSPC were enriched to Ͼ90% by positive selection with immobilized antibodies directed against surface CD34. As shown in Fig. 2 , following enrichment, CD34
ϩ HSPC were briefly cultured in the presence of IL-3, IL-6, and either SCF or LIF and then subjected to two rounds of transduction by spinoculation (2) with either LMiLy or L⌬MiLy supernatants. At 48 h past the final round of transduction, cells were stained for surface CD34, lineage markers (CD2, CD14, CD15, CD16, CD19, and glycophorin A), and Lyt2. Flow cytometric analysis of cells showed maintenance of the CD34-positive, LIN-negative phenotype on a majority of the cells, whether derived from CB or MPB, and further showed that a significant proportion (range, 8 to 35%) of the CD34 ϩ cells also expressed the Lyt2 marker (Fig. 3) . Sorting to Ͼ98% purity was achieved for CD34-positive, LIN-negative cells, and from 59 to 93% purity was achieved for Lyt2-positive cells (data not shown). The sorted cells were injected directly into the conjoint organs of irradiated SCID-hu mice in which the Thy/Liv grafts were of a disparate HLA background.
Reconstitution of SCID-hu Thy/Liv grafts with HLA-mismatched donor HSPC-derived thymocytes. Between 7 and 9 weeks post-HSPC transplantation, Thy/Liv grafts were removed and examined for donor cell content and phenotypic distribution of donor-derived thymocytes. As shown in Fig. 4A , MPB HSPC-derived thymocytes were identified by donor HLA and displayed a normal CD4 and CD8 distribution pattern typical of newly developing thymocytes, with ϳ90% of the cells falling within the CD4 ϩ CD8 ϩ immature thymocyte compartment and 5 to 10% and 1 to 5% of the cells falling within the more mature CD4 ϩ CD8 Ϫ and CD4 Ϫ CD8 ϩ compartments, respectively. In contrast, host cells (HLA disparate) displayed the characteristic reduction in immature CD4 ϩ CD8 ϩ thymocytes and preferential survival of mature phenotypes normally seen at this time following low-dose irradiation (unpublished observations).
Detection of Lyt2 transgene expression on donor-derived thymocytes. Freshly isolated thymocytes were examined for Lyt2 transgene expression and donor HLA. As shown in Fig.  4B , no cells from Thy/Liv grafts of nonreconstituted animals expressed the donor HLA marker MA2.1. Conversely, the majority of cells of animals transplanted with either mocktransduced or LMiLy-transduced MPB HSPC expressed the donor HLA marker and were therefore of donor origin (Fig.   4B ). Unlike their mock-transduced counterparts, in which no Lyt2 expression was observed, the LMiLy samples expressed Lyt2 in approximately 11% of all thymocytes for the sample shown in Fig. 4B (range in all reconstituted animals, 1 to 11%). When corrected for overall percentage of donor cells in the grafts, nearly 18% of all donor thymocytes were shown to express surface Lyt2, indicating that transgene expression could be maintained throughout the process of differentiation from HSPC to T cells. Similar results were obtained for CB HSPC reconstitutions, with surface Lyt2 expression being detected in 10 to 50% of donor-derived thymocytes in most animals (data not shown).
The distribution of transgene expression among the various thymocyte subpopulations in CB and MPB HSPC-reconstituted animals was examined by staining for surface CD4, CD8, and transgene-encoded Lyt2. The results for one MPB HSPCreconstituted animal are shown in Fig. 4C . The CD4 and CD8 distribution patterns for the mock-transduced and LMiLytransduced groups were nearly identical, with no obvious Lyt2 expression in the case of the mock group in any of the thymocyte compartments (data not shown). However, analysis of the
, and CD4 Ϫ CD8 ϩ thymocytes from LMiLy MPB HSPC-reconstituted grafts showed that 2.1, 13.5, and 3.5% of the cells respectively expressed Lyt2. After correcting these values to represent Lyt2 expression on donorderived cells, the percentages of transgene-expressing thymocytes were 10, 18.2, and 13%, respectively, for the CD4
, and CD4 Ϫ CD8 ϩ compartments. HIV-1 infection of thymocytes derived from transduced MPB HSPC. Donor-derived thymocytes from MPB HSPCreconstituted SCID-hu Thy/Liv grafts were enriched by fluorescent cell sorting on the basis of donor versus host HLA. Cells were further fractionated for surface CD4 and Lyt2 expression and subsequently expanded in vitro to obtain sufficient cell numbers. LMiLy and L⌬MiLy Lyt2-expressing cells were sorted to Ͼ90% purity prior to inoculation. Each of the sorted populations (LMiLy Lyt2 ϩ and L⌬MiLy Lyt2 ϩ ) were inoculated with the molecular isolate of HIV-1, JR-CSF, or with the clinical isolate, EW. Virus replication, as determined by measurement of p24, was assessed over time, and the results are given in Fig. 5 . In JR-CSF infections, the virus replicated to high levels in the Lyt2 ϩ L⌬MiLy control thymocytes (Fig. 5A ). For Lyt2 ϩ LMiLy thymocytes, p24 levels were too low to measure by ELISA, indicating that expression of the transgene conferred resistance to JR-CSF replication. The results for infection with EW were similar; however, the difference in p24 values between the two groups was less marked (Fig. 5B) . The virus did multiply in the Lyt2 ϩ LMiLy thymocytes, but replication was reduced by more than 1 order of magnitude as measured by the p24 ELISA. Similar results were obtained in a second experiment under identical conditions but using T cells derived in vivo from a different donor MPB (data not shown). In this second experiment, at 10 days postinfection, low but detectable levels of virus replication were observed for the RevM10-expressing T cells. Nonetheless, virus replication was still reduced by at least 2 log orders over values observed for control cells. These results suggest that RevM10-transduced HSPC are capable of differentiating into T cells in vivo and, as T cells, can produce sufficient RevM10 steady-state protein levels to inhibit virus replication.
DISCUSSION
This preclinical feasibility study is the first demonstration that MMLV-transduced HSPC can differentiate in vivo into the T-cell lineage and can express sufficient amounts of a FIG. 3 . Flow cytometric analysis of transduced CB and MPB HSPC prior to transplantation into host SCID-hu Thy/Liv grafts. 48 h after the last round of transduction, mock-transduced and LMiLy-transduced HSPC were stained for surface CD34, lineage markers (CD2, CD14, CD15, CD16, CD19, and glycophorin A), and transgene-encoded Lyt2.
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on February 23, 2013 by PENN STATE UNIV http://jvi.asm.org/ transgene-encoded protein (i.e., RevM10) to inhibit HIV replication in CD4 ϩ T cells. In many instances, input CB and MPB HSPC could be shown to expand over 1,000-fold in vivo during the differentiation process (Table 1) , and transgene expression could be detected in each of the CD4 and CD8 subcompartments of engrafted thymuses, suggesting that expression of RevM10 and the selection marker, Lyt2, did not have an inhibitory effect on thymopoiesis. Moreover, the physical manipulations during in vitro culture and transduction did not appear to impair the T-lineage potential of HSPC, adding further support to the feasibility of HSPC-based gene therapy.
In earlier reconstitution studies performed in SCID-hu Thy/ FIG. 4. Analysis of thymocytes from MPB HSPC-reconstituted SCID-hu Thy/Liv grafts. At 9 weeks post-HSPC transplantation, Thy/Liv grafts were harvested and examined for levels of donor cell reconstitution, phenotypic distributions of donor and host cells, and surface Lyt2 (transgene) expression. (A) Thymocytes derived from MPB HSPC were stained for detection of donor HLA (MA2.1 positive in a MA2.1-negative host background) and analyzed for total CD4 and CD8 expression, as well as donor-versus-host CD4 and CD8 expression. (B) Freshly isolated thymocytes from nonreconstituted control animals, animals reconstituted with mock-transduced MPB HSPC, or animals reconstituted with LMiLy-transduced MPB HSPC were stained for detection of donor HLA (MA2.1 positive in a MA2.1-negative host background) and transgene-encoded Lyt2. (C) Freshly isolated thymocytes from transduced MPB HSPC-reconstituted Thy/Liv grafts were stained for detection of CD4, CD8, and transgene-encoded Lyt2. Gates were set for CD4 ϩ CD8 Ϫ , CD4 ϩ CD8 ϩ , and CD4 Ϫ CD8 ϩ subpopulations and then analyzed for Lyt2 expression as shown in the histograms. Percentages of Lyt2 ϩ cells were determined after subtracting background noise observed in mock-transduced reconstituted controls. The Lyt2 ϩ percentages are given first for Lyt2 expression within the total (host plus donor) gated CD4-CD8 populations and then for Lyt2 expression on donor cells alone for each gated population.
Liv mice, in which we did not enrich for transduced HSPC, semiquantitative DNA PCR analysis revealed marking levels in CB HSPC-derived thymocytes equal to or below 0.1% (33) . In these studies, transgene expression could be measured in bulk only by RNA PCR or RNase protection assays. These marking frequencies are similar to those observed in large-animal studies and human clinical trials, in which postdifferentiation marking levels were determined to be, at best, in the 0.01 to 0.1% range (4, 12, 22) . Such marking efficiencies are in sharp contrast to those seen for HSPC progeny (10 to 30%) when assessed by standard in vitro assays which allow for the differentiation of B-cell, myeloid, and erythroid progeny (references 4, 12, and 32 and unpublished observations). Here, by preenriching for transduced HSPC via a transgene-encoded surface marker prior to transplantation, we have demonstrated progeny T-cell marking levels of up to 50%, whether measured by DNA PCR or by flow cytometric means (data not shown). In addition, the transgene-encoded surface marker allows us to quantitate expression at single-cell resolution.
In most experiments, when transduced HSPC preenrichment levels were greater than 80% for Lyt2-expressing cells, donor-derived T cells never displayed expression levels of a similar magnitude. The underlying cause of this discrepancy is unclear; however, there are a number of possible explanations. First, it is possible that at the time when transduced HSPC were being selected, Lyt2 was being expressed from episomal provirus DNA copies which later failed to integrate into the cellular genome. Second, over numerous rounds of cell division and as cells differentiated, transgenes may have been partially or entirely silenced by mechanisms governing expression, such as changes in chromatin structure, DNA methylation, or cis-acting silencing elements adjacent to the site of provirus integration (8) . Third, it is possible that a portion of the donor-derived T cells resulted from the disproportionate expansion of a fraction of nontransduced HSPC or other contaminating cells. Fourth, it is feasible that only a fraction of the HSPC CD34-positive, LIN-negative compartment has T-lineage potential and that the majority of the Lyt2 expression observed was in cells committed to other lineages, thereby masking the actual transduction level of multipotent HSPC. Finally, transgene expression may be differentially regulated by factors governed by a cell's state of activation. With respect to this last point, most mature thymocytes are relatively quiescent and nondividing. We are currently designing experimental strategies to help us better understand the mechanisms by which transgene expression is maintained or suppressed throughout the HSPC differentiation process.
While in this study we have not demonstrated that the CD34 ϩ cells we transduced had the hallmark self-renewing, multipotential characteristics of true stem cells, we have shown that within the MPB and CB CD34-positive, LIN negative compartment, we can attain reasonable levels of transduction, VOL. 71, 1997 RevM10 EFFICACY IN TRANSDUCED HSPC-DERIVED T CELLS 4713 rapidly enrich for transduced cells, and support T-cell differentiation of some of these cells in vivo. It is also important to note that in the SCID-hu model, we are transplanting across human allogeneic barriers, and it is not unreasonable to anticipate that engraftment, cell expansion, and perhaps even gene marking might be improved in an autologous setting. RevM10hasbeenshowntosuppressHIV-1replicationintrans-duced primary T cells (34, 42) . We have also tested RevM10 efficacy in both primary CD4 ϩ T cells and thymocytes and found that inhibition of viral replication is comparable to that observed in CD4 ϩ T cells derived in vivo from HSPC in the SCID-hu mouse (data not shown). When we placed Lyt2 ϩ -sorted HSPC-derived T cells in infection experiments with either a molecular isolate or a clinical isolate of HIV-1 (JR-CSF and EW, respectively), we observed greater than a 1-log reduction in viral replication relative to controls. These results suggest that HSPC-based RevM10 gene therapy can confer antiviral efficacy in the clinical setting.
The use of a transgene which encodes both a therapeutic element and a selectable surface marker may be a simple way by which transduced cells can be rapidly selected in vitro prior to transplantation. However, based on recent documentation of host immune responses against transgene selection elements such as hygromycin (35) , caution should be used in choosing the partner cell surface component for a therapeutic gene in a clinical vector. In the SCID-hu Thy/Liv model, the human thymus and hematopoietic components are intact but normal peripheral immune responses are minimal, and it is therefore unlikely that one would observe any host-versus-transgene response. In the clinical setting, in which a patient's peripheral T-cell compartment might be wholly or partially intact, use of the murine Lyt2 antigen would be inappropriate unless the host immune system becomes tolerant during the HSPC-to-Tcell differentiation process. Also, it is reasonable to assume that the transgene-encoded RevM10 protein could be immunogenic, which potentially could target transduced cells for an anti-RevM10 immune response. There are, however, two strong arguments to be made against the likelihood of this occurring. First, the progressive immunosuppression observed in most HIV-infected individuals, coupled with their failure to clear endogenous virions, suggests that their immune systems are no longer capable of responding adequately against HIV proteins or have become tolerant of them. Second, as transgene-carrying HSPC differentiate into T cells, autoreactive cells, or cells capable of recognizing RevM10 in the context of the host major histocompatibility complex, should be deleted or become anergic through the processes of negative selection and tolerance induction, respectively. Whether the difference between wild-type Rev and RevM10 is sufficient to elicit an immune response from a host's residual T-cell compartment is a matter for further consideration.
As we have shown for the first time in these proof of principle studies, T cells derived in vivo from RevM10-transduced HSPC are capable of inhibiting HIV replication. The next step is to demonstrate the in vivo efficacy of RevM10 in HSPCderived T cells in the SCID-hu setting. While the SCID-hu Thy/Liv model has been shown to support HIV replication and ultimately may provide the correct setting for assessing anti-HIV transgene efficacies in vivo, there still remain a number of questions which must first be answered before such an in vivo challenge approach is likely to yield interpretable results. Issues such as the ability of an infected thymic microenvironment to support HSPC differentiation, the potential adverse effects of HIV-mediated cytokine dysregulation on thymopoiesis, virus load, and possible indirect mechanisms of HIV-mediated killing are all subjects of current investigations.
It is apparent from the studies reported here that there is some degree of variability seen in reconstitution levels, marking levels, and transgene expression levels following in vivo differentiation of transduced HSPC in the SCID-hu Thy/Liv model. Some of this variation may be due to allogeneic transplantation effects, the quality of Thy/Liv grafts or donor HSPC, xenogeneic effects of the murine host, or mechanisms previously discussed. Despite these variables, it is clear that the SCID-hu Thy/Liv mouse model offers a unique in vivo T-cell differentiation system in which various aspects of HSPC-based gene therapy can be rapidly tested, whether targeting HIV infection, inherited disorders, or other indications. One can take advantage of this system's capacity to support differentiation of HSPC into various lineages to establish a nexus between gene transduction of HSPC and maintenance of transgene expression throughout differentiation into mature FIG. 5 . CD4-positive thymocytes derived from LMiLy-or L⌬MiLy-transduced MPB HSPC in vivo in SCID-hu Thy/Liv grafts were purified by flow cytometry via serial rounds of sorting for donor HLA (MA2.1 ϩ ) and CD4. LMiLy-transduced populations were further purified by sorting for transgene expressors (Lyt2 ϩ ) via flow cytometry. L⌬MiLy-transduced populations were purified on the basis of Lyt2 expression. Lyt2 ϩ populations were sorted to Ͼ90% purity. Sorted cells were challenged either with the molecular isolate of HIV-1, JR-CSF (A), or with the clinical isolate, EW (B). Virus replication was assessed over time by p24 ELISA. The error bars in panel B represent the standard errors of the means as determined from quadruplicate wells. In most instances, standard errors were so low that error bars were not displayed when data were plotted in log format.
progeny cells, in particular those of the T-cell lineage. Once we gain an understanding of this process and factors governing transgene expression throughout differentiation, this assay system can be used to help optimize gene transfer protocols, improve vector design, and ultimately assess transgene toxicity with respect to effects on HSPC differentiative potential and T-cell functions. 
